Tricyclic antidepressants (TCA) antibody and antigen (hapten, BSA/OVA conjugated)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-SMT-243-Ag01	BSA-Tricyclic antidepressants (TCA)	756
GMP-SMT-243-Ag02	OVA-Tricyclic antidepressants (TCA)	756
GMP-SMT-243-Ab01	Anti-human Tricyclic antidepressants (TCA) mouse monoclonal antibody (mAb)	1953
GMP-SMT-243-Ab02	Anti-human Tricyclic antidepressants (TCA) human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-SMT-243-Ag01
Product Name	BSA-Tricyclic antidepressants (TCA)
Target/Biomarker	Tricyclic antidepressants (TCA)
Expression platform	Synthetic
Isotypes	NA
Bioactivity validation	Tricyclic antidepressants (TCA) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in TCA level test of Neurodegenerative diseases/Pain () and related syndrome evaluation.
Tag	NA
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Tricyclic antidepressants (TCA) / OVA-Tricyclic antidepressants (TCA) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-243-Ag02
Product Name	OVA-Tricyclic antidepressants (TCA)
Target/Biomarker	Tricyclic antidepressants (TCA)
Expression platform	Synthetic
Isotypes	NA
Bioactivity validation	Tricyclic antidepressants (TCA) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in TCA level test of Neurodegenerative diseases/Pain () and related syndrome evaluation.
Tag	NA
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Tricyclic antidepressants (TCA) / OVA-Tricyclic antidepressants (TCA) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-243-Ab01
Product Name	Anti-human Tricyclic antidepressants (TCA) mouse monoclonal antibody (mAb)
Target/Biomarker	Tricyclic antidepressants (TCA)
Expression platform	Hybridoma
Isotypes	Mouse IgG
Bioactivity validation	Tricyclic antidepressants (TCA) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in TCA level test of Neurodegenerative diseases/Pain () and related syndrome evaluation.
Tag	mFc
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Tricyclic antidepressants (TCA) / OVA-Tricyclic antidepressants (TCA) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-243-Ab02
Product Name	Anti-human Tricyclic antidepressants (TCA) human monoclonal antibody (mAb)
Target/Biomarker	Tricyclic antidepressants (TCA)
Expression platform	Hybridoma
Isotypes	Mouse IgG
Bioactivity validation	Tricyclic antidepressants (TCA) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in TCA level test of Neurodegenerative diseases/Pain () and related syndrome evaluation.
Tag	mFc
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Tricyclic antidepressants (TCA) / OVA-Tricyclic antidepressants (TCA) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

1. Tricyclic Antidepressants (TCA): Comprehensive Overview and IVD Application Tricyclic Antidepressants (TCAs) represent a fundamental class of psychotherapeutic agents that have been instrumental in the management of depressive disorders, chronic neuropathic pain, and a spectrum of mood disorders. Mechanistically, TCAs exert their therapeutic effects by inhibiting the reuptake of central neurotransmitters, notably serotonin and norepinephrine, at synaptic junctions. This action results in increased neurotransmitter availability within the central nervous system, thereby ameliorating depressive symptoms and alleviating pain. Despite the emergence of newer pharmacological alternatives with more favorable side effect profiles, TCAs maintain a vital position in therapeutic protocols, particularly for patients who do not respond adequately to other antidepressants. The application of Tricyclic Antidepressants in In Vitro Diagnostics (IVD) is centered around their quantification for Therapeutic Drug Monitoring (TDM). The clinical utility of TDM in the context of TCA administration is multifaceted. Primarily, it serves to ensure that drug concentrations remain within a therapeutic range that maximizes efficacy while minimizing the risk of adverse effects. The necessity for such monitoring stems from TCAs' narrow therapeutic index and the considerable inter-individual variability in their pharmacokinetics and pharmacodynamics. Accurate measurement of TCA levels in blood or plasma samples is therefore critical for individualizing treatment regimens, optimizing therapeutic outcomes, and safeguarding patient well-being. Our biopharmaceutical company specializes in providing state-of-the-art anti-small molecule antibodies and competitive antigens tailored for the detection of TCAs in clinical samples. These reagents are pivotal for the development of highly sensitive and specific immunoassays, enabling the precise quantification of TCA concentrations. By facilitating robust TDM practices, our products play a crucial role in advancing personalized medicine and enhancing the quality of care for patients undergoing TCA therapy. 2. The Imperative for Measuring Tricyclic Antidepressants (TCA) The rationale for the meticulous measurement of Tricyclic Antidepressants encompasses several critical aspects of patient care and treatment optimization. Foremost among these is the imperative of Therapeutic Drug Monitoring (TDM). TDM of TCAs is integral for adjusting dosages to achieve desired therapeutic effects without crossing into the realm of toxicity. This balancing act is particularly challenging given the narrow therapeutic window of TCAs and the broad variability in how patients metabolize these drugs. Effective TDM can dramatically reduce the incidence of adverse drug reactions, which can range from mild anticholinergic effects to severe cardiotoxicity in cases of overdose. Additionally, accurate TCA quantification enables personalized treatment strategies. Genetic differences among individuals can significantly impact the metabolism of TCAs, leading to divergent therapeutic responses. By measuring TCA levels, healthcare providers can tailor treatments to the metabolic profile of each patient, thereby enhancing treatment efficacy and patient satisfaction. Monitoring TCA levels also plays a pivotal role in identifying non-compliance, a common challenge in managing chronic conditions like depression. Through quantitative analysis, clinicians can confirm whether patients are adhering to their prescribed medication regimens, facilitating timely interventions to address non-compliance issues. Our portfolio of anti-small molecule antibodies and competitive antigens for TCA detection embodies the cutting edge of IVD technology. These products are essential for the development of reliable, accurate assays that are critical for effective TDM, the realization of personalized medicine, and the overall improvement of therapeutic outcomes for patients treated with TCAs. This expanded description delves deeper into the scientific and clinical nuances of TCAs and their pivotal role in IVD, highlighting the advanced capabilities of your company's products in supporting personalized medicine and improving patient care through precise therapeutic drug monitoring.

About GDU